id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-N-1132-0116,FDA,FDA-2019-N-1132,Transcript - The Future of Insulin Biosimilars increasing access and facilitating the efficient development of biosimilar and interchangeable insulin products,Other,Transcript(s),2019-05-29T04:00:00Z,2019,5,2019-05-29T04:00:00Z,,2019-05-29T13:18:29Z,,0,0,0900006483cd08ce
FDA-2019-N-1132-0001,FDA,FDA-2019-N-1132,"The Future of Insulin Biosimilars: Increasing Access and Facilitating the
Efficient Development of Biosimilar and Interchangeable Insulin Products; Public Hearing; Request for Comments",Proposed Rule,Request for Comment,2019-04-03T04:00:00Z,2019,4,2019-04-03T04:00:00Z,2019-06-01T03:59:59Z,2019-06-26T01:02:18Z,2019-06438,0,0,0900006483b5e6e5